Putting Evidence Into Practice: Evidence-Based Interventions to Prevent, Manage, and Treat Chemotherapy-Induced Nausea and Vomiting

Tipton, Janelle; McDaniel, Roxanne W.; Barbour, Laurel; Johnston, Mary Pat; Kayne, M; Leroy, Patrícia Luz Almeida; Ripple, Marita L.

doi:10.1188/07.cjon.69-78

Cited by 92 publications

(62 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The source guidelines [12,13] did not address this question. It is clear that prophylaxis with a 5-HT3 antagonist alone leads to poor AINV control in patients receiving MEC and HEC.…”

Section: What Pharmacological Interventions Provide Optimalmentioning

confidence: 99%

“…The source guidelines [12,13] did not explicitly address this question and no pertinent evidence was identified. The recommendation reflects the consensus of the guideline panel.…”

Section: Primary Pediatric Literature Reviewmentioning

confidence: 99%

“…Of these, 13 guidelines were assessed using the AGREE instrument. Two guidelines were selected for adaptation; these were developed by The American Society of Clinical Oncology (ASCO) [11,12] and by Tipton et al [13]. When it became available, the 2011 update to the ASCO guideline [12] was compared to the previous version.…”

Section: Source Guideline Identificationmentioning

confidence: 99%

“…Although this guideline provides a general recommendation for AINV prophylaxis in children, its focus is on antiemetic use for adult cancer patients and it is in this capacity that the guideline is referenced as a source document. Tipton et al [13] was used as the framework for non-pharmacological interventions.…”

Section: Source Guideline Identificationmentioning

confidence: 99%

See 3 more Smart Citations

Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients

Dupuis

Boodhan

Holdsworth

et al. 2013

Pediatric Blood & Cancer

125

163

View full text Add to dashboard Cite

This guideline provides an approach to the prevention of acute antineoplastic‐induced nausea and vomiting (AINV) in children. It was developed by an international, inter‐professional panel using AGREE and CAN‐IMPLEMENT methods. Evidence‐based interventions that provide optimal AINV control in children receiving antineoplastic agents of high, moderate, low, and minimal emetogenicity are recommended. Recommendations are also made regarding selection of antiemetic agents for children who are unable to receive corticosteroids for AINV control, the role of aprepitant and optimal doses of antiemetic agents. Gaps in the evidence used to support the recommendations were identified. The contribution of this guideline to AINV control in children requires prospective evaluation. Pediatr Blood Cancer 2013; 60: 1073–1082. © 2013 Wiley Periodicals, Inc.

show abstract

“…The source guidelines [12,13] did not address this question. It is clear that prophylaxis with a 5-HT3 antagonist alone leads to poor AINV control in patients receiving MEC and HEC.…”

Section: What Pharmacological Interventions Provide Optimalmentioning

confidence: 99%

“…The source guidelines [12,13] did not explicitly address this question and no pertinent evidence was identified. The recommendation reflects the consensus of the guideline panel.…”

Section: Primary Pediatric Literature Reviewmentioning

confidence: 99%

Section: Source Guideline Identificationmentioning

confidence: 99%

Section: Source Guideline Identificationmentioning

confidence: 99%

See 2 more Smart Citations

Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients

Dupuis

Boodhan

Holdsworth

et al. 2013

Pediatric Blood & Cancer

125

163

View full text Add to dashboard Cite

show abstract

“…The American Society for Clinical Oncologists (ASCO) recently updated their guidelines for the use of antiemetics in oncology; their recommendations, with some additions, are detailed in TABLE 6 [37,38]. All have a high therapeutic index for CINV, and should be considered as first-line therapy [38].…”

Section: Chemotherapy-induced Nausea and Vomitingmentioning

confidence: 99%

Supportive care for women with gynecologic cancers

Chase¹,

Monk²,

Wenzel³

et al. 2008

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Real‐world emetic risk of chemotherapy and the corresponding antiemetic therapy in Japan: A study based on a nationwide database

Okuyama¹,

Boku

Higashi³

2021

Cancer Reports

View full text Add to dashboard Cite

Background Chemotherapy‐induced nausea and vomiting (CINV) is a major concern of patients with cancer, leading to suboptimal treatment. Aim This study assessed the emetic risk associated with intravenous and oral chemotherapy and the prophylactic antiemetic drugs by cancer type in a real‐world setting. Methods and Results We used the health services utilisation data for patients with cancer diagnosed in 2016. Patients aged at least 20 years at the time of diagnosis and who started their first course of chemotherapy were included. The emetic risk of chemotherapy was determined according to the cancer type and was classified based on clinical practice guidelines. The prescription of antiemetic drugs was assessed. Overall, 172 133 patients were evaluated, of whom 121 103 (70.4%) received intravenous chemotherapy. High‐emetic‐risk chemotherapy (HEC) was prescribed in 46 458 (27.0%) patients. HEC was prescribed most for patients with oesophageal cancer (80.3%), followed by malignant lymphoma (60.2%) and breast cancer (53.8%). Moderate‐emetic‐risk chemotherapy (MEC) was prescribed in 60 528 (35.2%) patients and was mostly prescribed for small cell lung cancer (59.9%). Meanwhile, more than 50% of the chemotherapy prescribed for patients with gastric, colorectal, and pancreatic cancer was low‐emetic‐risk chemotherapy. HEC was accompanied by three‐drug antiemetic prophylaxis in more than 90% of patients with small cell lung, non‐small cell lung, breast, and oesophageal cancer, whereas only 13.5% of patients with malignant lymphoma were administered CHOP (cyclophosphamide, doxorubicin, vincristine sulphate, and prednisolone) with prophylaxis. Conclusion The risk of CINV differs with cancer type. HEC was less prescribed compared with MEC. Most patients received the recommended anti‐emetic prophylaxis.

show abstract

Putting Evidence Into Practice: Evidence-Based Interventions to Prevent, Manage, and Treat Chemotherapy-Induced Nausea and Vomiting

Cited by 92 publications

References 34 publications

Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients

Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients

Supportive care for women with gynecologic cancers

Real‐world emetic risk of chemotherapy and the corresponding antiemetic therapy in Japan: A study based on a nationwide database

Contact Info

Product

Resources

About